Vancouver, BC, Canada, April 27, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted registration for its trademark DEFENCE THERAPEUTICS®.
This trademark is granted under registration number 7,033,299 for products such as “vaccines for human use; medicinal preparations for use in oncology; drug delivery agent in the form of an intracellular enhancer,” as well as for services consisting of “research and development of vaccines and medicines”.
This trademark registration represents a significant milestone for Defence as it continues to establish its brand as a leading biopharmaceutical company working to bring innovative vaccines and drug delivery technologies to market. DEFENCE THERAPEUTICS® represents the company’s commitment to innovation, research, and development, as well as its dedication to improving patient health outcomes through the creation of novel therapeutics.
Defence Therapeutic Inc. has an extensive pipeline of therapeutics in development, including vaccines for infectious diseases, cancer therapies, and drug delivery agents using its AccumTM platform technology. With the addition of the DEFENCE THERAPEUTICS® trademark, the company is well-positioned to continue its growth and success in the biopharmaceutical industry.
Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Cautionary Statement Regarding “Forward-Looking” Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.